CRVL

Business Context and Reporting Period

Company: CorVel Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: CorVel is an independent nationwide provider of medical cost containment and managed care services, primarily for workers' compensation and auto policies. The company operates in a single reportable segment (managed care) and serves insurance companies, third-party administrators, and self-insured employers.

Key Financial Metrics

Liquidity and Capital Resources

• Cash and Cash Equivalents: $14.7 million as of September 30, 2009 (includes $1.6 million in customer deposits).
• Working Capital: $26.2 million (Current Assets of $65.3 million less Current Liabilities of $37.2 million).
• Debt: No outstanding revolving loans. The company has a $10 million revolving credit facility with $6.3 million utilized for letters of credit.
• Share Repurchases: The company repurchased 581,323 shares for $16.8 million during the quarter and 610,999 shares for $17.4 million during the six-month period.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 5.9% quarter-over-quarter and 4.9% for the six-month period. Growth was driven by increased utilization of "Enterprise Comp" (patient management) and "CorCareRx" (network solutions) services.
• Profitability: Net income increased 28.9% for the quarter and 21.6% for the six-month period. Diluted EPS rose 38.9% to $0.50, aided by higher pre-tax income and a reduction in share count due to buybacks.
• Expense Management: General and administrative expenses decreased 4.8% for the quarter, primarily due to reduced systems and data interface costs and a reduction in employee headcount and consultants.
• Cost of Revenues: Increased 4.4% for the quarter, largely due to higher costs associated with high-cost services (CareIQ and CorCareRx) driven by increased demand.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management believes cash from operations and stock option exercises are adequate to fund obligations and share repurchases for the next twelve months. However, the company notes that revenue growth is uncertain due to a decline in national workers' compensation claims, price competition, and potential legislative changes in state workers' compensation laws.

Risks and Contingencies

• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting as of March 31, 2009, related to financial close and reporting processes (e.g., use of Excel for consolidation, lack of timely reconciliations). Remediation activities, including implementing new accounting system consolidation capabilities, were underway but not yet fully validated as effective.
• Litigation: A putative class action lawsuit filed in 2005 by Kathleen Roche, D.C., alleges failure to direct patients to PPO network providers and use of biased software. The class was certified, and appeals were denied. The company cannot estimate the potential loss but intends to defend vigorously.
• Market Risks: Declines in manufacturing employment and workplace injuries may reduce the volume of claims, directly impacting revenue. Competition from larger entities and potential in-house outsourcing by customers also pose risks.

Investor Verification Checklist

• Internal Control Remediation: Verify the status of the material weakness remediation and whether the new accounting consolidation system has been fully validated for the fiscal year-end.
• Litigation Exposure: Monitor developments in the Roche class action lawsuit, as an unfavorable outcome could be material.
• Share Count Dilution/Accretion: Confirm the impact of ongoing share repurchases versus stock option exercises on future EPS.
• Revenue Drivers: Assess the sustainability of the growth in "Enterprise Comp" and "CorCareRx" utilization given the broader decline in workers' compensation claims.
• Liquidity Usage: Track the usage of the $10 million credit facility and the pace of share repurchases against available cash reserves.